Table 1.
Outcomes reported in each trial of the network. Ave: avelumab; Axi: axitinib; Ipi: ipilimumab; Nivo: nivolumab; NR: not reached; ORR: objective response rate; OS: overall survival; Pembro: pembrolizumab; PFS: progression-free survival.
| Study | Treatment | Number of Patients | ORR (95% CI) |
Median OS (Months) |
Median PFS (Months) |
HR OS (95% CI) | HR PFS (95% CI) |
|---|---|---|---|---|---|---|---|
| CheckMate 214 | Sunitinib | 546 | 32% (28–36) |
37.9 | 12.3 | - | - |
| Nivo + Ipi | 550 | 39% (35–43) |
NR | 12.4 | 0.71 (0.59–0.86) |
0.85 (0.73–0.98) |
|
| Keynote 426 | Sunitinib | 429 | 35.7% (31–40) |
NR | 11.1 | - | - |
| Pembro + Axi | 432 | 59% (54–64) |
NR | 15.1 | 0.53 (0.38–0.74) |
0.69 (0.57–0.84) |
|
| Javelin Renal 101 | Sunitinib | 444 | 25% (22–30) |
NR | 8.4 | - | - |
| Ave + Axi | 442 | 51% (47–56) |
NR | 13.8 | 0.78 (0.55–1.08) |
0.69 (0.56–0.84) |